home / subscribe / donate / books / archives / search / links / feedback / events / faq
The New Print Edition of CounterPunch, Only for Our Newsletter Subscribers! Meet the Real John McCain:
North Vietnam's Go-To CollaboratorRead how the Vietnamese protected and promoted McCain and how in return he danced to their tune. McCain was on Vietnamese radio so often he was tagged as "the PW Songbird". SUBSCRIBE NOW to read the true story of Glory Boy McCain, only in our newsletter. Also in this issue: Alexander Cockburn on the final fall of Bill Clinton, lobbyist for torturers. PLUS Serge Halimi on what "free trade" really means when the going gets rough. Get your copy today by subscribing online or calling 1-800-840-3683 Contributions to CounterPunch are tax-deductible. Click here to make a donation. If you find our site useful please: Subscribe Now! CounterPunch books and gear make great holiday presents.Order CounterPunch By Email For Only $35 a Year !
|
Today's Stories April 30, 2008 William P. O'Connor April 29, 2008 Uri Avnery Roedad Khan Chris Floyd Paul Craig Roberts Dave Lindorff Mats Svensson Peter Morici Mike Ferner John Weisheit Amit Srivastava Website of the Day April 28, 2008 JoAnn Wypijewski Mike Whitney Iris Keltz Steve Niva David Macaray John Ross Stephen Lendman Malou Innocent Christopher Brauchli William Kaufman Website of the Day April 26 / 27, 2008 Alexander Cockburn Ralph Nader Peter Camejo Harvey Wasserman Franklin Lamb Wajahat Ali Mike Whitney Andrew Wimmer David Yearsley Greg Moses Ron Jacobs Robert Fantina Missy Comley Beattie Linn Cohen-Cole Paul Krassner Jeffrey St. Clair Poets' Basement Website of the Weekend April 25, 2008 George Ciccariello-Maher Dave Lindorff Franklin Lamb Alan Farago John W. Farley Kathleen M. Barry Mohammed Alireza Nick Dearden Carmelo Ruiz Marrero Bruce Springsteen Website of the Day
April 24, 2008 Linn Washington, Jr. Franklin Lamb Jennifer Van Bergen Joanne Mariner Mark Engler Dave Lindorff John Blair De Clarke / Stan Goff Binoy Kampmark Philippe Marlière Peter Morici Website of the Day
Cockburn / St. Clair Vijay Prashad Paul Craig Roberts Stephen Soldz Laura Santina John Stauber / Dave Lindorff George Ciccariello-Maher Ralph Nader John Weisheit Website of the Day April 22, 2008 David Isenberg Stan Cox David Macaray Jeff Birkenstein Mike Whitney Nikolas Kozloff Floyd Rudmin Carlos Villarreal Ray McGovern Michael Gould-Wartofsky Robert Ovetz Pat Wolff Website of the Day
Bill Quigley Uri Avnery Dave Lindorff Wajahat Ali Andy Worthington Robert Jensen Ron Jacobs Dan Bacher Harvey Wasserman Danny Alexander Website of the Day April 19 / 20, 2008 Alexander Cockburn Patrick Cockburn Wajahat Ali Andrew Wimmer Rev. William E. Alberts David Rosen Robert Fantina Ramzy Baroud Saul Landau Dr. Susan Block David Yearsley Phyllis Pollack Jeffrey St. Clair Poets' Basement April 18, 2008 John Ross Dave Lindorff Dan Glazebrook Carl Finamore Rannie Amiri Richard Morse Ko Young-dae Farooq Sulehria
April 17, 2008 Michael Hudson Robert Bryce Kathy Kelly Madis Senner Peter Morici Ron Jacobs William S. Lind James Murren Ben Terrall Walter Brasch Website of the Day
April 16, 2008 Bill Kauffman Roxanne Dunbar-Ortiz Saul Landau Peter Morici Eric Toussaint / Jeff Ballinger David Macaray Gary Leupp Richard Morse George Ciccariello-Maher Dave Lindorff Website of
the Day
April 15, 2008 Ralph Nader Uri Avnery Brian Cloughley David Price Joe Bageant Steve Early Mats Svensson Michael Donnelly April Howard / Laray Polk Charles Modiano Website of
the Day
April 14, 2008 Carl Finamore Michael Hudson M. Shahid Alam Patrick Cockburn Paul Craig Roberts Joanne Mariner Martha Rosenberg Dave Lindorff P. Sainath John V. Whitbeck Website of the Day
April 12 / 13, 2008 Alexander Cockburn Patrick Cockburn Mike Whitney David Yearsley Robert Fantina Conn Hallinan Bill Hatch Ramzy Baroud George S. Hishmeh Ron Jacobs Nikolas Kozloff Charles Thomson Alexander Billet Missy Beattie David Michael Green Seth Sandronsky Prairie Miller Jeffrey St.
Clair Poets' Basement Website of
the Weekend
April 11, 2008 Nikolas Kozloff Wajahat Ali Sharon Smith Yigal Bronner
/ Neve Gordon Alan Farago Dave Lindorff George Wuerthner Christopher
Brauchli Website of the Day
April 10, 2008 Mathieu Vernerey Elizabeth Schulte David Macaray Ashley Smith Peter Morici Jacob Hornberger Harold Austin Website of the Day
April 9, 2008 Paul Craig
Roberts Winslow T.
Wheeler C. Hand Paul Krassner Paul Wolf Wajahat Ali Karyn Strickler Dan La Botz Eric Walberg Robin Millenthal Website of the Day April 8, 2008 Mike Whitney Nikolas Kozloff Greg Moses Joshua Frank John Ross Michael Donnelly John V. Walsh Jeff Nygaard Bill Piper Sen. Russ Feingold Website of the Day
April 7, 2008 Ishmael Reed Harry Browne
Uri Avnery Lenni Brenner Ayesha Ijaz Khan Robert Fisk Edwin Krales Chris Genovali Website of the Day
April 5 / 6, 2008 Alexander Cockburn Ramzy Baroud Ralph Nader David Yearsley Saul Landau Paul Craig
Roberts Lawrence Korb / Ian Moss Seth Sandronsky John Ross Robert Fantina David Michael Green Missy Beattie Patrick Bond Dr. Susan Block Phyllis Pollack Adam Engel Jeffrey St. Clair Poets' Basement Website of the Weekend
![]()
![]()
Subscribe Online |
April 30, 2008
The Fruits of Innovation Must be Available to People Who Need ThemMedical R&D That Works in the Developing WorldBy ROBERT WEISSMAN Can the world settle on a medical research and development (R&D) system that develops medicines and other products to meet priority health needs and makes those products available on an affordable basis? Developing a strategy to meet these twin goals is the task of World Health Organization (WHO) negotiations in their final phase this week. The WHO Intergovernmental Working Group on Public Health, Innovation and Intellectual Property is finishing talks to create a global strategy and plan of action to spur medical R&D focused on the health needs of developing countries, and to ensure that poor populations get access to important pharmaceuticals and other medical technologies. The world -- and especially developing countries -- needs more innovation. To have public health benefit, however, the fruits of the innovative process must be available to people who need them. The current patent monopoly-based system of R&D has proven inefficient at advancing a needs-driven public health agenda. This is true for rich countries as well as poor, but the situation is much worse in poor countries. This has nothing to do with the ethics of Big Pharma. It is how the system is designed. The current corporate sector system of R&D is driven by the prize offering of a patent monopoly. Patents are not worth much if they offer monopolies on sales to a population that -- no matter how large -- has little buying power. And if the prize incentive is too small, it will not induce R&D, no matter how much it may be needed as a public health matter. Here's what this means in practice: Developing countries comprise 80 percent of the world’s population but amount to only 13 percent of the global market for medical products. A review by Doctors Without Borders of new drugs introduced between 1975 and 2004 found that of 1,556 new drugs put on the market, only 21 were for "neglected diseases" -- diseases endemic to developing countries. The value of the patent monopoly is based on the holder using it to profit maximize as a monopolist. It is therefore no surprise that companies holding patent monopolies charge high prices. This is what the patent enables. High prices are an increasing problem in rich countries, but the brand-name pharmaceutical industry's current pricing model -- which commonly runs into the thousands of dollars a year for a single medicine, and may involve charges of more than $100,000 -- leaves new medicines completely out of reach of the vast majority in developing countries. How to respond to these problems? There are two basic alternatives. One is to rely on charity. Private foundations and companies seeking good will may contribute to R&D for products targeting diseases in developing countries. They may offer discounted versions of their drugs, or give some away. Charitable initiatives may accomplish quite a bit, but in general they suffer from being ad hoc, unsustainable, erratic, episodic, short-lived and insufficiently resourced. Charity may be helpful, but it is no solution to meeting public health priorities on a sustained basis. The second option is to examine systemic approaches to support R&D that do not rely on patent monopolies or the prospect of charging high drug prices as a reward, and to identify mechanisms to make the fruits of R&D widely accessible. There are a lot of good ideas, large and small, about how to do this. Notably at the WHO talks, Bolivia and Barbados have put forward a series of concrete proposals for non-patent prizes to incentivize R&D, with the resulting fruits of the innovation made available at competitive prices. One of the Bolivia/Barbados proposals is for a Priority Medicines and Vaccines Prize Fund. The fund would offer large cash prizes to entities developing new products for neglected diseases, antibiotics or products for emerging public health threats (like avian flu or SARS). It would offer smaller prizes to parties that made advances toward these goals, meeting benchmarks short of bringing new products to market. It would also offer separate prize money to parties that openly published and shared their research. A condition of receiving the prizes would be licensing all resulting patent, data and know-how so that end products could be made available immediately on a competitive basis. In other words, there would immediately be generic competition and low-cost pricing. There is no guarantee that the prize fund would work in creating innovation where now there is none or much too little. But it is an interesting and provocative proposal. There is no legitimate rationale, on the merits, to oppose ongoing discussion of this prize proposal. Remember, in keeping with the focus of the WHO talks, the Bolivia/Barbados proposal focuses on health problems specific to developing countries. It involves areas where there is no effective market (or, in the case of antibiotics, special market problems) to incentivize R&D. So, there is nothing for Big Pharma to lose here. But the industry and its allies are viewing this and similar proposals very cautiously. Some ideologues oppose any tinkering with the patent monopoly system. The industry is concerned that tinkering in the case of health problems related to developing countries will eventually threaten the patent monopoly system in the rich world, or interfere with its ability to expand sales to the wealthy in middle-income countries. (More on the role of Big Pharma and its proxies in my next column.) Will country negotiators at the WHO talks ignore those who would subordinate public health to patent veneration or commercial concerns? Will they instead advance experiments with new institutional arrangements to promote the complementary public health objectives of innovation and access? We will know by the end of the week. Robert Weissman is editor of the Washington, D.C.-based Multinational Monitor and director of Essential Action.
![]()
|
How the Press Led the US into War ![]() Buy End Times Now! CounterPunch Books of the Crossroads: HOW THE IRISH INVENTED SLANG By Daniel Cassidy AMERICAN BOOK AWARD! ![]() Click Here to Buy! Click Here for Dates & Venues Michael Neumann's Devastating Rebuttal of Alan Dershowitz ![]() Click Here to Buy! Saul Landau's Bush and Botox World with a Foreword by Gore Vidal ![]() Click Here to Order! How They Made a Killing on the War on Terrorism ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() The Occupation by Patrick Cockburn ![]() ![]() ![]() Humanitarian Imperialism By Jean Bricmont ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() CITY BEAUTIFUL By Tennessee Reed ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |